What is Anamorelin and its indications

Anamorelin(Anamorelin) is a new oral Ghrelin receptor agonist, which is considered to be one of the innovative drugs in the field of cancer cachexia treatment. It simulates the effect of "ghrelin" by selectively activating the growth hormone secretagogue receptor GHS-R1a, promoting appetite and increasing energy intake in the central nervous system. It also stimulates the secretion of growth hormone and insulin-like growth factor-1 (IGF-1), improving muscle protein synthesis and weight loss.

Anamorelin was first developed by Japan's Otsuka Pharmaceutical and is mainly used to treat cancer cachexia in patients with unresectable or recurrent non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer. Cancer cachexia is a metabolic syndrome characterized by loss of appetite, muscle atrophy, and weight loss. It is common in patients with advanced tumors. There is currently no radical treatment. The emergence of anamorelin provides these patients with a non-invasive, long-term oral drug option.

It can not only significantly improve appetite and weight, but also improve quality of life and physical status to a certain extent, helping patients better tolerate chemotherapy or targeted therapy. According to the scope of use approved by the Japanese Food and Drug Administration, anamorelin is suitable for adult patients with malnutrition and weight loss caused by tumors, especially those with poor nutritional treatment effects. Clinical observation shows that it takes effect quickly and can usually improve appetite and energy intake within a few days to a week. However, the drug may also cause certain adverse reactions, such as electrocardiogram changes, abnormal heart rhythm, increased liver function indicators, etc., so it needs to be used rationally under the guidance of a doctor.

Overall, anamorelin has brought new treatment ideas to patients with cancer cachexia through its uniqueGhrelin pathway regulatory mechanism. In the future, as more countries gradually review and market it, this drug is expected to become one of the important drugs in the clinical comprehensive management of cancer nutritional disorders.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/